Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05582304 · ClinicalTrials.gov registry record · NA
Role of Glare and Spectral Filtering on Contrast Sensitivity: A Pilot Study
A NA study of Visual Acuity, sponsored by Johnson & Johnson Vision Care.
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT05582304: Completed NA study of Visual Acuity, sponsored by Johnson & Johnson Vision Care.
NCT05582304 is a NA study of Visual Acuity that has completed, run by Johnson & Johnson Vision Care. The registered enrollment target is 40 participants, below the 138-participant average among 20 other Visual Acuity trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05582304, a NA study of Visual Acuity, has completed, sponsored by Johnson & Johnson Vision Care.
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This will be a split-plot design, randomized, parallel, double-masked feasibility study to evaluate the role of a test lens on contrast sensitivity with and without glare.
Primary Outcome
Photopic contrast sensitivity was measured under bright light conditions (\~120 cd/m2) with a broadband glare source at five spatial frequencies (1.6, 3.2, 8, 16 and 24 cpd) using the University of Georgia system. The area under the log contrast sensitivity function (AULCSF) was derived by first calculating the logarithm of contrast sensitivity as logCS = log10(contrast sensitivity), and then AULCSF was calculated using logCS and the log (base 10) of each spatial frequency based on the trapezoid
Conditions Studied
Interventions
- DEVICE Test Lens
- DEVICE Control Lens
Study Locations (1)
Georgia
- University of Georgia - Athens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2022-10-31 |
| Est. Completion | 2022-12-08 |
| Phase | NA |
What the finished NCT05582304 record still lists
NCT05582304 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 138-participant average among 20 other Visual Acuity trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Visual Acuity appearing as the primary indexed condition, and to 2 interventions - of which Test Lens is the first listed.
NCT05582304 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT05582304 about?
NCT05582304 is a clinical study titled "Role of Glare and Spectral Filtering on Contrast Sensitivity: A Pilot Study". This will be a split-plot design, randomized, parallel, double-masked feasibility study to evaluate the role of a test lens on contrast sensitivity with and without glare.
What is the current status of trial NCT05582304?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2022-10-31. Estimated completion is 2022-12-08.
What conditions does trial NCT05582304 study?
This clinical trial studies the following conditions: Visual Acuity.
What interventions are being tested in trial NCT05582304?
The interventions under investigation include: Test Lens (DEVICE), Control Lens (DEVICE).
Who is sponsoring clinical trial NCT05582304?
This trial is sponsored by Johnson & Johnson Vision Care, which has 142 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05582304 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Visual Acuity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05582304's enrollment target sits among peer trials
40 18th of 20 higher than 3 of 20 other Visual Acuity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Visual Acuity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Effect of Scatter on Visual Performance
RECRUITING · NA
-
Clinical Evaluation of a Reusable Multifocal Optical Design in a Presbyopic Population Phase 2
COMPLETED · NA
-
Evaluation of Daily Disposable Silicone Hydrogel Multifocal Toric Contact Lenses
COMPLETED · NA
-
Pilot Dispensing Study of Two Marketed Daily Disposable Multifocal Contact Lenses
COMPLETED · NA
-
Clinical Evaluation of Approved Contact Lenses
COMPLETED · NA
-
Clinical Assessment of Visual Function With the Acrysof ReSTOR Multifocal IOL
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI